LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.27 -3.79

Buy Sell

Overview

Share price change

24h

Current

Min

1.26

Max

1.32

Key metrics
By Trading Economics
Income	2.7M -24M
EPS	-0.354
Employees	171
EBITDA	-5.3M -28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+108.59% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-615K 80M
Previous open	5.06
Previous close	1.27

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 mar 2026, 17:19 UTC

Major News Events

Chubb to Assume Risk, Issue Policies for $20 Billion Strait of Hormuz Insurance Facility

20 mar 2026, 16:56 UTC

Major News Events

Week Ahead for FX, Bonds: PMI Data to Show Middle East War's Impact on Sentiment

20 mar 2026, 16:56 UTC

Major News Events

Week Ahead for FX, Bonds: PMI Data to Show Middle -2-

20 mar 2026, 16:45 UTC

Major News Events

The Week in Oil: U.S. Seeks to Ease Concerns Over War But Supply Risks Mount

20 mar 2026, 16:22 UTC

Major News Events

NYMEX Overview: Petroleum Futures Rise, Leaving Most Contracts on Track for Solid Weekly Gains -- OPIS

20 mar 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

20 mar 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

20 mar 2026, 19:55 UTC

Market Talk

Major News Events

Brent Crude Closes Out Volatile Week Higher -- Market Talk

20 mar 2026, 19:28 UTC

Market Talk

Major News Events

Natural Gas Falls as Traders Sell Ahead of the Weekend -- Market Talk

20 mar 2026, 19:28 UTC

Acquisitions, Mergers, Takeovers

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

20 mar 2026, 18:39 UTC

Market Talk

Gold Settles With Largest Weekly Dollar Decline on Record -- Market Talk

20 mar 2026, 18:31 UTC

Acquisitions, Mergers, Takeovers

Honeywell Announces Pricing of Debt Tender Offers >HON

20 mar 2026, 18:19 UTC

Acquisitions, Mergers, Takeovers

Why Mayo and Soap No Longer Mix for Unilever -- Update

20 mar 2026, 18:15 UTC

Market Talk

iMarkets May Be Wrong in Pricing for Canadian Rate Increases -- Market Talk

20 mar 2026, 17:57 UTC

Market Talk

U.S. Oil Rig Count Inches Up -- Market Talk

20 mar 2026, 17:04 UTC

Major News Events

Chubb to Assume Risk, Issue Policies for $20B Strait of Hormuz Insurance Facility

20 mar 2026, 16:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

20 mar 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

20 mar 2026, 15:40 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Unilever, McCormick Deal Makes Strategic Sense, But Risk Remains -- Market Talk

20 mar 2026, 15:30 UTC

Earnings

Gemini Space Station's Earnings 'Better Than Feared.' Can They Save the Stock? -- Barrons.com

20 mar 2026, 15:26 UTC

Market Talk

Earnings

Major News Events

Lands' End: War Impacts Weighing on Some European Consumers -- Market Talk

20 mar 2026, 15:26 UTC

Acquisitions, Mergers, Takeovers

Why Mayo and Soap No Longer Mix for Unilever -- WSJ

20 mar 2026, 15:25 UTC

Market Talk

Gilt Selloff Shows Vulnerability of U.K.'s Economy -- Market Talk

20 mar 2026, 15:19 UTC

Market Talk

Major News Events

UBS Raises Oil Price Forecast as Middle East Conflict Escalates -- Market Talk

20 mar 2026, 14:58 UTC

Major News Events

Chevron Jumps Into Top 20 Most Valuable U.S. Companies. The Iran War's Other Big Stock Movers. -- Barrons.com

20 mar 2026, 14:55 UTC

Market Talk

Major News Events

Gold Lower as Speculative Pullback Extends -- Market Talk

20 mar 2026, 14:54 UTC

Acquisitions, Mergers, Takeovers

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

20 mar 2026, 14:53 UTC

Acquisitions, Mergers, Takeovers

Unilever, McCormick Deal Would Create a New Condiment King -- WSJ

20 mar 2026, 14:46 UTC

Market Talk

U.K. Government Bonds Selloff More Pronounced Than Peers -- Market Talk

20 mar 2026, 14:45 UTC

Market Talk

Major News Events

Oil Price Forecasts For 2026-27 Raised at UBS -- Market Talk

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

108.59% upside

12 Months Forecast

Average 2.67 USD 108.59%

High 3 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.